{"ticker": {"uuid": "11edaee8-2de2-4156-bd5e-7e5863551caa", "symbol": "ORMP", "name": "Oramed Pharmaceuticals Inc.", "exchange": "TLV", "country": "IL", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "ORMP SEC Filings - Oramed Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE12dU8tZnhBblA4VWhYSlZRSWVKb1RYTGYwcXJydVB3RlowaWljQWVJQncwLTR4QU9mTEVoME5halVaemZrSzUzNkFod1FvOFYtUDg2a0lSUDE2NmZpUkxmdVlBTVNaQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-21T17:26:43+00:00", "published_display": "21 Jun 2026 17:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5GSlFnbDJ6WHlReWpuTnVudXgtc2E4Wl82MVlyMGw4a19BVk1lWUJRQVZhQUtCOElxdUNlVnlwMV9ma0psNHJIMHhBdGIxT3haRENkdEF1eTRqSGZFNWtGMTUybzU5SlNoeGY0bkhpS3Q?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T07:47:48+00:00", "published_display": "18 Jun 2026 07:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Valuation: PE, PB & Fair Value Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE1VaWN5aC1PY29DMFFLaTJtcFNGWkZYdHVxWmtOcS1ibl9uNGtNd2ltRnl1TGlKMEp4dFJmdXVIU1d3aC1WdU1yd052TkFZbTVqQVRDbGNqUEtrZEl5UTlIb05XSVZReTJFdmdOMVNpeXQtcG5GdFlGcENwRQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T06:52:06+00:00", "published_display": "18 Jun 2026 06:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE9xUy1GWFJ4Q2dDSzMtWEhaNmh1Sm9mYk9Ha2dmTU9BUGxyZ1BfQ3BDLWJNMFhrdEJOaWowSzNJSmhmajlMVWpIckg0R1pzUXgxYkZIOXNQV3lrWGZ1c1FsaU9UYnJKMU5PcnBwRHp5cUs?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T01:03:27+00:00", "published_display": "18 Jun 2026 01:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed (ORMP) Set to Join Russell 2000 and 3000 Indexes in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNUWFPbTZMS2xOeU1uNTJxZ29seFVzQ25hYUdLZGRRN045MXRLOWV3eVAxQTFZYzJHMVVMTzJpeGU4NlY3MTVjemc3RGRsMDdoWEpsLVZZOXJIV1p1R3BmczVZQlpCU1RtYXQ5SVFkTjdVZGI3NFhHdExfbnFjMTZMR05xVmNFZFFzWXRZT1VyVTZ6VFo2VXMtY3pqbzdlQnl0RzdiN1pYakxuWHFPYnNHdGxn?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-17T19:52:30+00:00", "published_display": "17 Jun 2026 19:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFB0SDVRX19rYVVBeWxobkdfeHBMcG12eFFaczh5MjlHMjJOVjhENFBtS01hak54bGdvTElLeDBVMDFyMmNoWktLQ01uRTlzU1VDUUN6UzNIWHNKejV0MU4yRS1OQkhPN3NRWVR4empEVlNmUnB4OEd3MA?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T13:57:11+00:00", "published_display": "17 Jun 2026 13:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed wins Russell 2000 and 3000 inclusion on June 29", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQLUJQQzN6eWdudjlVR2c3elMxMGlVMGdEZDAzRXdrTm91REpsd21USlJtQTdZNzQ2dGF5TVd2NEMxaWQ5RVdaWG5Lczl2NTRRTGtzRzB4NjQwcVgwQlI5cTR3Uy1QOWVSbU5BTGVob0tkbm9fR2ZDWnBGWDh5MXNURFY2TnkyNmxLQTZudHhDTmJMV2ZBSE01UXZpbnlrSHUwUHVmOGtBT21nX1N5Y2ZvVXNsQS1rQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T12:55:00+00:00", "published_display": "17 Jun 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxONmpPQmZvbGJpM1R4MTR6WHhUVVV0eHFLZjhkaW5oamlpWS1kZWZ1OFVjcTdiaW5iS0EtbTdhMHg2OU9jSlE1UUNOZXVuWFpmSWlRNW1kUEhFdlA0c1FZMDZXNy1Ec1J3bDFoLURQV3lUOHNjVng0RjNQZ3RsOURnRlprRGd4bTRhdXlZSHJDUDl4UzJhZzlXbnA0eXBmWGhiYkxabUFFUlVJaG50M2RmeGhMXzJRbG15NDNPYS1rUm5GQ0c2T0l6VllvOEdLMWc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals (NASDAQ: ORMP) notifies late Q1 2026 Form 10-Q filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQT0VQR1lqbUw0VlVPYWFqc2xwUGpBeVRUMlNaTVBOdFVaLVYyRVViaXJWMWw2Z2ltcHpFb0JYUEw3RV9HOFItTHUyTzFCdU5xVzRObEhJaVR4ckFuMFFqVGMxYkV6VE5lamlVWVAxN3dpRy1wdm1yeXotT1RkZmN2N3FjdVM3VVgyN1NBcDFKX01PQXNBX2gzOXJSeUM2YXl1LVdJdUpLLUl6UVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquamarine reports 5.06% stake in Oramed (ORMP) via Schedule 13G", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQczdMbjBMWFBIdUNOMGRycXFxbXJHYWF2T18zdmVRSnZBSV9qaEdYcGV6c2dVNGdxVFlmaDg0ZWFuSDgwNk53LTB0WDd3cFhsT2hkbWpNYldKTy04YzNBUERqdmxPS3R5a3dxcFlrbmZHVUl6M3hZdWQ4SjlNakE0LTBaMnp0VHFqTEtMZDVtb3ZGRG55SGV0YS0wX3JxOHdBVkNrLXhjLVF2SWE1SHlST09Rb2ZwU3pkNkxYa0RfU0EtSGpPM2dub0M3VQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals stock (US68403P1003): Shares surged 7.98% to $2.30", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPeU9fRE0xSXp0Sk1CVUJFY0twMHo0T2FJcU1qS3RiVHBzaVBxS0ZHaUEyVU1NMGZuUHFfRWtJYkNQT054WlpUZnhXeDctbkFIdDJHNzgtdTl6bWdkNzQtQ1ZnclBFZkNLRnN4SlVhWFc0UF9iTTFydm5UY0tiNXJDX0NUSTNzc1FaWHBobnp3alg0b0xGendHSWpRd3kwdFJMTkhxbTlMMWxFOWg4R2xaTDExOFg0bVIxQ3FKSkR2TTZoejYzUHc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed (NASDAQ: ORMP) CEO uses 44,818 shares to cover RSU tax withholding", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPbGE3azBUN2NMOTlwVmVROWctRjlCcVltUUVXLU1YMmEyTWtMcU9CYVlLekUzV1pxSHRTeld3ZWFFVXBvWE9QMXJtN2ZFYnMzVUF5SjVDd3A2RzlwV2g2NlZJbDBrVi1BTUVDV1ItQnItQllYeTh2S1RTUzdPdVVNaFZ1TjJJdGplSm55ZWRMZVh2Zzdua3NrazZveGktVk1KTndaVkl1TkZBTnA5OXdHV3FpNG1sMWxUR1cwQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NNDM Stock In Focus: Nano Dimension Pops A Poison Pill Days After Oramed Stake Build-Up", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQVDhuTldpeWNKUXpCZmdlT3h2NVBpQm8ySmdwZlpCaW9Xa3pFTXJWeEpqbXM0S01CTkVpVWNvYTZyYndIOU56dV9ISFBJZFhXeFE5dEItYVN6eS0wNGE2bHdpMnRQRE9zMFhuU0ozTVRlZnBJa25FdDJOVW9rbGpGdXdWVkpCLXRVbWpHXzNDek9wNVZ6QjU0YUtKQk5rYTFtc0RldmVtQUdnQlZheXh1WUFvekJQRFh0NkdoTFhLazVISlVqMWRUV2JHVGlTWGVvM3pYNl9hYVBhbEdGc1h0Vm5DN0o?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed and Lifeward Announce Strategic Transaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOczBySEF1Vy1BNUR4d2x2ejFfa1YtMnd3djB4bEJ1V2IwWkczZy01a19ybkpUT1FkYndqa3JQTTNLcURXc0lYUXl0aHNGYnQzR1l1WVM5dzFiSXBSTmxEbDZSTi1MU3kzX2pwRmdMdm1BaEduSEpvZ3RkRUthLWhhaGxndnJkd2lJU1lGeERIX2dvYlp3bW94Y1c3UUlhLXExYlV1Q3NUZnVGQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed stock rises after receiving $18 million payment from Scilex By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNbVdPOVF4S3NfZGRLWWh2YXRoZFpsV2RUcmg2dmJaRHk0amt5LVJ4aGNLXzdYMDcwNG5DYzdyNWlaT2RvNVNWTjR3TFllY3k5MlUyTGRCaUVKOE9ia19EVlNoSTRFbkNzWUdPdklHdFZqcThnRjVDS1ZkbHpXd0d2XzRxYmVpZlh5UDZkSmVZZThpY3VZQ0VsbGREVTMxMmI3NlF3aEUwMjFlMmV4STRQMkN0RFM0Y3JjOS1qaTItemZIUjFy?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxPc3NEdVhOTFlFQ0NyS2E4aHR3UGNiVjBCMjZpZTNUSm5VQnNWSDgyTlFDZTRoNzh5aWdlZkdGczc3TzZhbE5tQlpYWGpablZvZHpYVUg1WVBueFpsMGs5Ql81T01ScFBYWVF0ZUpoNHRYR0hvVERSMFNBejcwQ1ZUcVlSWG5RZ0JFRUY2aGpENTFlOUEwb1VPVHU3NXI3Z2hFLVBNZ2UyN3FseVFzSXVSakpRWHloR3o4bk5LVE1zWkw4cF9KT3E4OHJCRXFlWTZUbzhkb0VnT2J0T0RDeUNnXzZSV0lBZ1BGXzUzVWNpb25YZUR3TUZCQkhCR1l0T25wV2lEYkN5dkRWOGt4WU5yQmtR?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQYUdKeDVjTlhrTUlxSjV4TmtFWU15NzZBUFJFT3pCVWZqSkdpLW8tdzBTSUkyQTRQXzViZjdraWhRVnZIRkVOT05Bckl4ZjhFMUtsRkN5NEZicnd5TXhVcTNwSUlPY1huRWRRM0VxVHJRVEZDNF9sVTZwXzhZSnQ4S3pveGp0RnJjbmF2YkhhdnFOMmdSNm02ejlvbWNEMkUxYWo2amdrdjRWNFlwRlBleTk0VEJJVFND?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-21T08:00:00+00:00", "published_display": "21 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "PR Newswire", "published_at": "2021-11-19T08:00:00+00:00", "published_display": "19 Nov 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed: Chinese partner building plant for our product - Globes", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQbUprZGdRWWdPaHFnd3F4X2ktb2w0WXZpTGFlSTJlTm9uUWFqOUlnWktSc0JUS0xsR1VWSVQxakRVeUtvUU9YaGlRX3Z4M3Z5czE0MEEzOE9kaTlnNjFwSTdFY2hXU2owNlpseVR4c1VGS25JbzYteFplRlBTOWVtcHh5UjFWWFBGb1FFSGFGdGpJTGN0QkQtdE92UmhDYktj?oc=5", "source_name": "Israel Business News", "published_at": "2016-11-17T08:00:00+00:00", "published_display": "17 Nov 2016 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc. (ORMP) Stock | $50 Million Licensing and Investment Agreement", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "warriortradingnews.com", "published_at": "2015-12-01T08:00:00+00:00", "published_display": "01 Dec 2015 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5wYTNPM2tOa2JqT1Y0U0R3VDExaTFMZnR2U096NGlyd1JjQ1dZQ0VBQmt2ZmRPZndoY0twRmZxZDhwWjNkY19pMFN5N2ZKaFgwYVpxa1gxZ3U3Zw?oc=5", "source_name": "MarketBeat", "published_at": "2015-06-12T10:21:26+00:00", "published_display": "12 Jun 2015 10:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ORMP SEC Filings - Oramed Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE12dU8tZnhBblA4VWhYSlZRSWVKb1RYTGYwcXJydVB3RlowaWljQWVJQncwLTR4QU9mTEVoME5halVaemZrSzUzNkFod1FvOFYtUDg2a0lSUDE2NmZpUkxmdVlBTVNaQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-21T17:26:43+00:00", "published_display": "21 Jun 2026 17:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5GSlFnbDJ6WHlReWpuTnVudXgtc2E4Wl82MVlyMGw4a19BVk1lWUJRQVZhQUtCOElxdUNlVnlwMV9ma0psNHJIMHhBdGIxT3haRENkdEF1eTRqSGZFNWtGMTUybzU5SlNoeGY0bkhpS3Q?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T07:47:48+00:00", "published_display": "18 Jun 2026 07:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Valuation: PE, PB & Fair Value Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE1VaWN5aC1PY29DMFFLaTJtcFNGWkZYdHVxWmtOcS1ibl9uNGtNd2ltRnl1TGlKMEp4dFJmdXVIU1d3aC1WdU1yd052TkFZbTVqQVRDbGNqUEtrZEl5UTlIb05XSVZReTJFdmdOMVNpeXQtcG5GdFlGcENwRQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T06:52:06+00:00", "published_display": "18 Jun 2026 06:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE9xUy1GWFJ4Q2dDSzMtWEhaNmh1Sm9mYk9Ha2dmTU9BUGxyZ1BfQ3BDLWJNMFhrdEJOaWowSzNJSmhmajlMVWpIckg0R1pzUXgxYkZIOXNQV3lrWGZ1c1FsaU9UYnJKMU5PcnBwRHp5cUs?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T01:03:27+00:00", "published_display": "18 Jun 2026 01:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed (ORMP) Set to Join Russell 2000 and 3000 Indexes in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNUWFPbTZMS2xOeU1uNTJxZ29seFVzQ25hYUdLZGRRN045MXRLOWV3eVAxQTFZYzJHMVVMTzJpeGU4NlY3MTVjemc3RGRsMDdoWEpsLVZZOXJIV1p1R3BmczVZQlpCU1RtYXQ5SVFkTjdVZGI3NFhHdExfbnFjMTZMR05xVmNFZFFzWXRZT1VyVTZ6VFo2VXMtY3pqbzdlQnl0RzdiN1pYakxuWHFPYnNHdGxn?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-17T19:52:30+00:00", "published_display": "17 Jun 2026 19:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFB0SDVRX19rYVVBeWxobkdfeHBMcG12eFFaczh5MjlHMjJOVjhENFBtS01hak54bGdvTElLeDBVMDFyMmNoWktLQ01uRTlzU1VDUUN6UzNIWHNKejV0MU4yRS1OQkhPN3NRWVR4empEVlNmUnB4OEd3MA?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T13:57:11+00:00", "published_display": "17 Jun 2026 13:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed wins Russell 2000 and 3000 inclusion on June 29", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQLUJQQzN6eWdudjlVR2c3elMxMGlVMGdEZDAzRXdrTm91REpsd21USlJtQTdZNzQ2dGF5TVd2NEMxaWQ5RVdaWG5Lczl2NTRRTGtzRzB4NjQwcVgwQlI5cTR3Uy1QOWVSbU5BTGVob0tkbm9fR2ZDWnBGWDh5MXNURFY2TnkyNmxLQTZudHhDTmJMV2ZBSE01UXZpbnlrSHUwUHVmOGtBT21nX1N5Y2ZvVXNsQS1rQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T12:55:00+00:00", "published_display": "17 Jun 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxONmpPQmZvbGJpM1R4MTR6WHhUVVV0eHFLZjhkaW5oamlpWS1kZWZ1OFVjcTdiaW5iS0EtbTdhMHg2OU9jSlE1UUNOZXVuWFpmSWlRNW1kUEhFdlA0c1FZMDZXNy1Ec1J3bDFoLURQV3lUOHNjVng0RjNQZ3RsOURnRlprRGd4bTRhdXlZSHJDUDl4UzJhZzlXbnA0eXBmWGhiYkxabUFFUlVJaG50M2RmeGhMXzJRbG15NDNPYS1rUm5GQ0c2T0l6VllvOEdLMWc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals (NASDAQ: ORMP) notifies late Q1 2026 Form 10-Q filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQT0VQR1lqbUw0VlVPYWFqc2xwUGpBeVRUMlNaTVBOdFVaLVYyRVViaXJWMWw2Z2ltcHpFb0JYUEw3RV9HOFItTHUyTzFCdU5xVzRObEhJaVR4ckFuMFFqVGMxYkV6VE5lamlVWVAxN3dpRy1wdm1yeXotT1RkZmN2N3FjdVM3VVgyN1NBcDFKX01PQXNBX2gzOXJSeUM2YXl1LVdJdUpLLUl6UVE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aquamarine reports 5.06% stake in Oramed (ORMP) via Schedule 13G", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQczdMbjBMWFBIdUNOMGRycXFxbXJHYWF2T18zdmVRSnZBSV9qaEdYcGV6c2dVNGdxVFlmaDg0ZWFuSDgwNk53LTB0WDd3cFhsT2hkbWpNYldKTy04YzNBUERqdmxPS3R5a3dxcFlrbmZHVUl6M3hZdWQ4SjlNakE0LTBaMnp0VHFqTEtMZDVtb3ZGRG55SGV0YS0wX3JxOHdBVkNrLXhjLVF2SWE1SHlST09Rb2ZwU3pkNkxYa0RfU0EtSGpPM2dub0M3VQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals stock (US68403P1003): Shares surged 7.98% to $2.30", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPeU9fRE0xSXp0Sk1CVUJFY0twMHo0T2FJcU1qS3RiVHBzaVBxS0ZHaUEyVU1NMGZuUHFfRWtJYkNQT054WlpUZnhXeDctbkFIdDJHNzgtdTl6bWdkNzQtQ1ZnclBFZkNLRnN4SlVhWFc0UF9iTTFydm5UY0tiNXJDX0NUSTNzc1FaWHBobnp3alg0b0xGendHSWpRd3kwdFJMTkhxbTlMMWxFOWg4R2xaTDExOFg0bVIxQ3FKSkR2TTZoejYzUHc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed (NASDAQ: ORMP) CEO uses 44,818 shares to cover RSU tax withholding", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPbGE3azBUN2NMOTlwVmVROWctRjlCcVltUUVXLU1YMmEyTWtMcU9CYVlLekUzV1pxSHRTeld3ZWFFVXBvWE9QMXJtN2ZFYnMzVUF5SjVDd3A2RzlwV2g2NlZJbDBrVi1BTUVDV1ItQnItQllYeTh2S1RTUzdPdVVNaFZ1TjJJdGplSm55ZWRMZVh2Zzdua3NrazZveGktVk1KTndaVkl1TkZBTnA5OXdHV3FpNG1sMWxUR1cwQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NNDM Stock In Focus: Nano Dimension Pops A Poison Pill Days After Oramed Stake Build-Up", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQVDhuTldpeWNKUXpCZmdlT3h2NVBpQm8ySmdwZlpCaW9Xa3pFTXJWeEpqbXM0S01CTkVpVWNvYTZyYndIOU56dV9ISFBJZFhXeFE5dEItYVN6eS0wNGE2bHdpMnRQRE9zMFhuU0ozTVRlZnBJa25FdDJOVW9rbGpGdXdWVkpCLXRVbWpHXzNDek9wNVZ6QjU0YUtKQk5rYTFtc0RldmVtQUdnQlZheXh1WUFvekJQRFh0NkdoTFhLazVISlVqMWRUV2JHVGlTWGVvM3pYNl9hYVBhbEdGc1h0Vm5DN0o?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed and Lifeward Announce Strategic Transaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOczBySEF1Vy1BNUR4d2x2ejFfa1YtMnd3djB4bEJ1V2IwWkczZy01a19ybkpUT1FkYndqa3JQTTNLcURXc0lYUXl0aHNGYnQzR1l1WVM5dzFiSXBSTmxEbDZSTi1MU3kzX2pwRmdMdm1BaEduSEpvZ3RkRUthLWhhaGxndnJkd2lJU1lGeERIX2dvYlp3bW94Y1c3UUlhLXExYlV1Q3NUZnVGQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed stock rises after receiving $18 million payment from Scilex By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNbVdPOVF4S3NfZGRLWWh2YXRoZFpsV2RUcmg2dmJaRHk0amt5LVJ4aGNLXzdYMDcwNG5DYzdyNWlaT2RvNVNWTjR3TFllY3k5MlUyTGRCaUVKOE9ia19EVlNoSTRFbkNzWUdPdklHdFZqcThnRjVDS1ZkbHpXd0d2XzRxYmVpZlh5UDZkSmVZZThpY3VZQ0VsbGREVTMxMmI3NlF3aEUwMjFlMmV4STRQMkN0RFM0Y3JjOS1qaTItemZIUjFy?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxPc3NEdVhOTFlFQ0NyS2E4aHR3UGNiVjBCMjZpZTNUSm5VQnNWSDgyTlFDZTRoNzh5aWdlZkdGczc3TzZhbE5tQlpYWGpablZvZHpYVUg1WVBueFpsMGs5Ql81T01ScFBYWVF0ZUpoNHRYR0hvVERSMFNBejcwQ1ZUcVlSWG5RZ0JFRUY2aGpENTFlOUEwb1VPVHU3NXI3Z2hFLVBNZ2UyN3FseVFzSXVSakpRWHloR3o4bk5LVE1zWkw4cF9KT3E4OHJCRXFlWTZUbzhkb0VnT2J0T0RDeUNnXzZSV0lBZ1BGXzUzVWNpb25YZUR3TUZCQkhCR1l0T25wV2lEYkN5dkRWOGt4WU5yQmtR?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQYUdKeDVjTlhrTUlxSjV4TmtFWU15NzZBUFJFT3pCVWZqSkdpLW8tdzBTSUkyQTRQXzViZjdraWhRVnZIRkVOT05Bckl4ZjhFMUtsRkN5NEZicnd5TXhVcTNwSUlPY1huRWRRM0VxVHJRVEZDNF9sVTZwXzhZSnQ4S3pveGp0RnJjbmF2YkhhdnFOMmdSNm02ejlvbWNEMkUxYWo2amdrdjRWNFlwRlBleTk0VEJJVFND?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-21T08:00:00+00:00", "published_display": "21 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "PR Newswire", "published_at": "2021-11-19T08:00:00+00:00", "published_display": "19 Nov 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed: Chinese partner building plant for our product - Globes", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQbUprZGdRWWdPaHFnd3F4X2ktb2w0WXZpTGFlSTJlTm9uUWFqOUlnWktSc0JUS0xsR1VWSVQxakRVeUtvUU9YaGlRX3Z4M3Z5czE0MEEzOE9kaTlnNjFwSTdFY2hXU2owNlpseVR4c1VGS25JbzYteFplRlBTOWVtcHh5UjFWWFBGb1FFSGFGdGpJTGN0QkQtdE92UmhDYktj?oc=5", "source_name": "Israel Business News", "published_at": "2016-11-17T08:00:00+00:00", "published_display": "17 Nov 2016 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals Inc. (ORMP) Stock | $50 Million Licensing and Investment Agreement", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "warriortradingnews.com", "published_at": "2015-12-01T08:00:00+00:00", "published_display": "01 Dec 2015 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5wYTNPM2tOa2JqT1Y0U0R3VDExaTFMZnR2U096NGlyd1JjQ1dZQ0VBQmt2ZmRPZndoY0twRmZxZDhwWjNkY19pMFN5N2ZKaFgwYVpxa1gxZ3U3Zw?oc=5", "source_name": "MarketBeat", "published_at": "2015-06-12T10:21:26+00:00", "published_display": "12 Jun 2015 10:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 79, "total_relevant": 23, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 22, "score": 51, "total": 23, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 88, "events": [{"event": "general", "label": "Market update", "weight": 10.6, "count": 18}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 1135.0, "latest_week": "2026-06-19", "one_week_move": 2.1, "four_week_move": -9.1, "twelve_week_move": 10284.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.397846, "market_dynamics_buy_signal": false, "relative_strength": 884.163592, "fair_value_gap": 1949.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 51.348, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.1% over one week, -9.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "PR Newswire", "count": 3}, {"label": "Seeking Alpha", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "GuruFocus", "count": 1}, {"label": "AD HOC NEWS", "count": 1}, {"label": "Stocktwits", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 23}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 18}, {"label": "Deals and strategy", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Earnings", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "88/100 classification confidence."}, {"label": "Company focus", "value": "23", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.1% over one week, -9.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ORMP SEC Filings - Oramed Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms"}], "updated_at": "2026-06-23T04:45:17.238109+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}